PSMA antibody, humanized PSMA.CAR10.3, or Cetuximab increases prostate cancer localization of NF-κB p50-deficient immature myeloid cells (p50-IMC) and phagocytosis by their macrophage progeny.

Saved in:
Bibliographic Details
Title: PSMA antibody, humanized PSMA.CAR10.3, or Cetuximab increases prostate cancer localization of NF-κB p50-deficient immature myeloid cells (p50-IMC) and phagocytosis by their macrophage progeny.
Authors: Alzubi MA; Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University, CRB I, Rm. 253, 1650 Orleans St., Baltimore, MD, 21231, USA., Barberi T; Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University, CRB I, Rm. 253, 1650 Orleans St., Baltimore, MD, 21231, USA., Friedman AD; Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University, CRB I, Rm. 253, 1650 Orleans St., Baltimore, MD, 21231, USA. afriedm2@jhmi.edu.
Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2025 Feb 04; Vol. 74 (3), pp. 95. Date of Electronic Publication: 2025 Feb 04.
Publication Type: Journal Article
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1432-0851
DOI:10.1007/s00262-024-03939-4